VSEL Stem Cell Isolation and Differentiation for Tissue Repair

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current strategies for isolating and using stem cells for regenerative therapies face challenges in controlling the growth and differentiation of embryonic stem cells, particularly human embryonic stem cells, which limits their application in treating tissue and organ damage without requiring immunosuppressive therapy and efficiently isolating and purifying stem cells from adult animals.

Innovation Solution

The method involves isolating and culturing very small embryonic-like (VSEL) stem cells from bone marrow, umbilical cord blood, or peripheral blood, using specific antibodies and growth factors to form embryoid body-like spheres, and then differentiating them into desired cell types, such as neuronal, endodermal, or cardiomyocyte cells, for tissue repair.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If embryonic stem cells are used for regenerative therapy, then the ability to differentiate into multiple cell types is improved, but the need for immunosuppressive therapy increases

Engineering Contradiction:

Improvedifferentiation potentialVSAvoidimmunosuppression requirement

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses very small embryonic-like (VSEL) stem cells as a copy or alternative to traditional embryonic stem cells. VSEL cells exhibit similar pluripotent differentiation capabilities but can be derived from the patient's own bone marrow, creating an autologous copy that avoids immune rejection while maintaining the ability to differentiate into multiple cell types

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent introduces VSEL cells as an intermediary between embryonic stem cells and adult stem cells. These cells possess embryonic-like pluripotency but can be obtained from adult bone marrow, serving as a mediator that provides differentiation potential without requiring the ethical and immunological complications of traditional embryonic stem cell therapy

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If stem cells are isolated and cultured for therapy, then the ability to treat tissue damage is improved, but the complexity of isolation and purification processes increases

Engineering Contradiction:

Improvetissue repair efficacyVSAvoidisolation and purification process

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent changes the identification parameters from complex multi-marker immunophenotyping to a simple size-based parameter. VSEL cells are identified as a very small cell population (3-5 μm diameter) in the bone marrow, allowing isolation through size-based separation techniques rather than complex antibody-based sorting, thereby reducing procedural complexity while maintaining purification efficacy

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS9155762B2Uses and isolation of stem cells from bone marrow

Publication Date: 2015.10.13 UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION INC

AI summary

The presently disclosed subject matter provides populations of stem cells that are purified from bone marrow, peripheral blood, and/or other sources. Also provided are methods of using the stem cells for treating tissue and/or organ damage in a subject.